Shenzhen Neptunus Interlong Bio-technique Company Limited (HKG:8329)
0.1150
+0.0020 (1.77%)
Aug 27, 2026, 2:33 PM HKT
HKG:8329 Revenue
Shenzhen Neptunus Interlong Bio-technique Company had revenue of 476.09M CNY in the half year ending December 31, 2025, a decrease of -6.53%. This brings the company's revenue in the last twelve months to 912.25M, down -8.14% year-over-year. In the year 2025, Shenzhen Neptunus Interlong Bio-technique Company had annual revenue of 972.01M, down -6.69%.
Revenue (ttm)
912.25M CNY
Revenue Growth
-8.14%
P/S Ratio
0.18
Revenue / Employee
660.10K CNY
Employees
1,382
Market Cap
189.61M HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 972.01M | -69.69M | -6.69% |
| Dec 31, 2024 | 1.04B | -23.16M | -2.18% |
| Dec 31, 2023 | 1.06B | 78.17M | 7.92% |
| Dec 31, 2022 | 986.69M | 147.89M | 17.63% |
| Dec 31, 2021 | 838.81M | -192.56M | -18.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zhongzhi Pharmaceutical Holdings | 1.93B |
| Lee's Pharmaceutical Holdings | 1.44B |
| Kontafarma China Holdings | 914.71M |
| Wai Yuen Tong Medicine Holdings | 683.44M |
| Qianhai Health Holdings | 453.03M |
| Tianda Pharmaceuticals | 350.53M |
| PuraPharm Corporation | 336.11M |
| Extrawell Pharmaceutical Holdings | 51.48M |